MarketBeat
02 Oct 2026, 08:02 UTC · 10h ago
Verdict
Headline takes no side. We score PRQR +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
ProQR reported the first human validation of its Axiomer RNA-editing platform via AX-0810, showing dose-dependent target engagement and up to an eightfold increase in serum total bile acids.
Newpublished 2026-10-02 reporting first-in-human data
So whatPlatform validation expands the addressable pipeline beyond retinal disorders, potentially increasing the company's valuation multiple.
More positive than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
The next-generation candidate AX-0811 has entered a phase I study with initial data from the first two cohorts expected in early January 2027.
Newpublished 2026-10-02 reporting upcoming data
So whatThis creates a binary catalyst event within the next 3 months that will determine the lead asset for the biliary atresia program.
More positive than 87% of claims this week
AX-0811 preclinical data showed a 67% reduction in both hepatocyte bile acid levels and histological cholestasis scores in a humanized mouse model.
Newpublished 2026-10-02 citing preclinical results
So whatIf these 67% reductions translate to humans, it would significantly improve the probability of success for the mid-2028 Phase II interim analysis.
More positive than 79% of claims this week
AX-0811 is projected to have a half-life of more than three months, potentially allowing for dosing less frequently than once per quarter.
Newpublished 2026-10-02 reporting projections
So whatIncreased durability compared to AX-0810's eight-week half-life improves patient compliance and commercial competitiveness in the pediatric market.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported positive first-in-human data for AX-0810, providing clinical validation for its RNA-editing platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Benzinga
23h ago
+0.3%
Price flat so far
$1.64 vs $1.63 close before publication (Oct 1) · not market-adjusted
PRQR chart →
